RT Journal Article
SR Electronic
T1 The St. Gallen 2019 Guidelines understages the Axilla in Lobular Breast Cancer – a Population-Based Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.08.21258532
DO 10.1101/2021.06.08.21258532
A1 Ulrik Narbe
A1 Pär-Ola Bendahl
A1 Mårten Fernö
A1 Christian Ingvar
A1 Looket Dihge
A1 Lisa Rydén
YR 2021
UL http://medrxiv.org/content/early/2021/06/12/2021.06.08.21258532.abstract
AB Background The St. Gallen 2019 guidelines recommend omission of completion axillary lymph node dissection (cALND) in breast cancer patients with 1-2 sentinel lymph node (SLN) metastases regardless of histopathology. Concurrently, adjuvant chemotherapy is endorsed for luminal A-like disease with ≥4 axillary lymph node (ALN) metastases. We aimed to estimate the proportion of patients with invasive lobular cancer (ILC) and invasive ductal cancer of no special type (NST) and 1-2 SLN metastases for whom cALND would indicate need of adjuvant chemotherapy.Methods Patients with ILC and NST histopathology undergoing primary surgery 2014-2017 were identified in the Swedish National Quality Breast Cancer register. After exclusion of patients with incongruent or missing data, 1886 patients who fulfilled the St. Gallen 2019 criteria for cALND omission were included in the study cohort.Results Patients with ILC (n = 329) had a higher metastatic nodal burden and more often a luminal A-like subtype compared with NST patients (n = 1507). The prevalence of ≥ 4 ALN metastases was higher in ILC (31%) than in NST (15%), corresponding to an adjusted odds of 2.26 (95% CI 1.59-3.21). Luminal A-like breast cancers with ≥4 ALN metastases were overrepresented in ILC cases (52/281 (19%)) compared to NST cases (43/1299 (3%)), P<0.001.Conclusions Patients with ILC more often had a luminal A-like breast cancer with ≥4 ALN metastases compared with NST patients. Abstaining cALND in patients with luminal A-like ILC with 1-2 SLN metastases warrants future attention as it risks nodal understaging and hence undertreatment in one-fifth of these patients.Source of funding The authors declare no conflicts of interest. The Skåne County Councils Research and Developmental Foundation, the Governmental Funding of Clinical Research within the National Health Service (ALF), the Swedish Cancer Society, the Erling Persson Family Foundation, Kronoberg County Council’s Research and Development Foundation, The Cancer Foundation Kronoberg, The Swedish Research Council and The Swedish Breast Cancer Association. The funding agencies had no role in study design or interpretation of data.Previous communication Preliminary findings were published as part of Ulrik Narbe’s doctoral thesis.Trial registration ISRCTN registry: ISRCTN14341750Competing Interest StatementThe authors have declared no competing interest.Clinical TrialISRCTN14341750Funding StatementThe Skane County Councils Research and Developmental Foundation the Governmental Funding of Clinical Research within the National Health Service (ALF) the Swedish Cancer Society the Erling Persson Family Foundation Kronoberg County Councils Research and Development Foundation The Cancer Foundation Kronoberg The Swedish Research Council and The Swedish Breast Cancer Association The funding agencies had no role in study design or interpretation of dataAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Review Committee in SwedenAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset used during the current study are available from the corresponding author on reasonable request.